CYCSP38: A Potential Drug Target and Biomarker (G360184)

Target Name: CYCSP38

NCBI ID: G360184

CYCSP38

Other Name(s): Cytochrome c, somatic pseudogene 38 | HCP38 | CYCS pseudogene 38 | HC2

CYCSP38: A Potential Drug Target and Biomarker

Cytochrome c, somatic pseudogene 38 (CYCSP38) is a gene that encodes a protein known for its role in cell signaling pathways. The CYCSP38 protein is a key regulator of the p53 protein, which is a well-known tumor suppressor protein that plays a crucial role in preventing the development of cancer.

The identification of CYCSP38 as a potential drug target and biomarker has significant implications for the development of new cancer therapies. Cancer is a leading cause of human mortality, and there is a growing need for effective treatments to combat this disease. The discovery of CYCSP38 as a potential drug target and biomarker could lead to the development of new treatments that specifically target this protein and have minimal side effects on normal cells.

CYCSP38 is a transmembrane protein that is expressed in a variety of tissues, including muscle, heart, and brain. It is a member of the superfamily of cytochrome c enzymes, which are involved in the production of reactive oxygen species (ROS) that can damage cellular components and contribute to the development of oxidative stress-induced diseases.

CYCSP38 is regulated by multiple genetic and signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These pathways are involved in cell signaling, cell adhesion, and cell survival, and are known to be involved in the development of cancer.

The CYCSP38 protein is known for its role in the regulation of the p53 protein. The p53 protein is a well-known tumor suppressor protein that plays a crucial role in preventing the development of cancer. It is expressed in high levels in cancer cells and is known to be involved in the development of cancer.

CYCSP38 is a key regulator of the p53 protein, and studies have shown that it plays a crucial role in the regulation of p53 function. CYCSP38 is known to interact with the p53 protein and prevent it from being degraded. This interaction between CYCSP38 and p53 is important for the maintenance of p53 function and the regulation of cellular processes.

CYCSP38 is also known for its role in the regulation of cellular apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body. Apoptosis is a critical mechanism for maintaining tissue homeostasis and is involved in the development of diseases such as cancer.

CYCSP38 is involved in the regulation of apoptosis through its interaction with the Bcl-2 protein. Bcl-2 is a protein that is known for its role in the regulation of apoptosis, and is a potential drug target for cancer therapies.

CYCSP38 has also been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. These pathways are involved in cell signaling, cell adhesion, and cell survival, and are known to be involved in the development of cancer.

The TGF-β pathway is a signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. It is known to be involved in the development of cancer, and therapeutic interventions that target TGF-β have been shown to be effective in the treatment of cancer.

The PI3K/Akt pathway is a signaling pathway that is involved in the regulation of cell signaling pathways, including cell survival and angiogenesis. It is known to be involved in the development of cancer, and therapeutic interventions that target PI3K/Akt have been shown to be effective in the treatment of cancer.

CYCSP38 is known to be involved in the regulation of TGF-β and PI3K/Akt signaling pathways, and these pathways are

Protein Name: CYCS Pseudogene 38

The "CYCSP38 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYCSP38 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets